Innate Pharma S.A. (IPHA)
| Market Cap | 160.74M |
| Revenue (ttm) | 20.83M |
| Net Income (ttm) | -51.22M |
| Shares Out | 92.16M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | 1.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,871 |
| Open | 1.710 |
| Previous Close | 1.700 |
| Day's Range | 1.710 - 1.770 |
| 52-Week Range | 1.290 - 3.511 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+521.47%) |
| Earnings Date | Sep 11, 2025 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]
Financial Performance
In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price target is $11.0.
News
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for ...
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...
Outcome of Innate Pharma's 2025 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer...
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the q...
Innate Pharma announces conference call and webcast for Q1 2025 business update
MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registra...
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel a...
Innate Pharma Announces €15M Investment by Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscri...
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Coll...
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO ...
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its nov...
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.
Innate Pharma: Moving Into The Padcev Space
Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA...
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...